09 Jan2019
Written by admin. Posted in News
Announcement
Deadline for pre-proposal submission is: 7 March 2019 (17:00 CET)
ERA PerMed is an ERA-NET Cofund, supported by 32 partners of 23 countries and cofunded by the European Commission (EC). To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 31 funding organisations have agreed to launch the second Joint Transnational Call for research projects in Personalised Medicine (PM). This represents the first of three potential additional calls non-cofunded by the EC. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals. The available budget for this call is 30 Mio € (approx.).
-
Opening of online submission tool: 9 January 2019
-
Submission deadline for pre-proposals: 7 March 2019 (17:00 CET)
-
Submission deadline for full-proposals: 17 June 2019 (17:00 CEST)
Electronic submission website
Electronic proposal submission is mandatory on: https://ptoutline.eu/app/erapermed2019. Research project consortia who intend to submit a transnational proposal should register as soon as possible, by clicking on “Sign up” and follow further instructions.
Contact person for the Joint Call Secretariat (JCS):
The ERA PerMed JCS is hosted by The French National Research Agency (ANR):
Monika Frenzel
50 Avenue Daumesnil, 75012 Paris, FRANCE
Tel: +33 (0) 1 73 54 83 32
CALL Documents
Call documents have been updated on 18/01/2019: new funding agency (ASRT, Egypt) joint the JTC2019.
AIMS OF THE CALL
With its second transnational call, ERA PerMed will foster research and innovation activities building close linkages between basic biomedical research, clinical research, bioinformatics, epidemiology, socio-economic research, as well as research on the integration of PM into clinical practice and on ethical, legal and social implications. The overarching goal is to improve disease management, with better patient stratification, diagnostics and treatment protocols, and disease prevention. Proposals submitted under this call are expected to demonstrate the applicability of project outcomes into clinical practice as well as to describe the impact on the health care systems.
The overall objectives of the ERA PerMed call are (i) to support translational research projects in the field of Personalised Medicine; (ii) to encourage and enable interdisciplinary collaborations towards implementation of PM, in combining pre-clinical and/or clinical research with computational components and research on relevant ethical, legal and social aspects (ELSA) and/or research on the optimisation of health care systems; (iii) to encourage collaboration between academia (research teams from universities, higher education institutions, public research performing institutions), clinical/public health research (research teams from hospital/ public health institutions, healthcare settings and other healthcare organisations) and private partners e.g. SMEs (small and medium-sizes enterprises).
Scope OF THE CALL
Proposals must be interdisciplinary and clearly demonstrate the potential impact on PM as well as the added value of transnational collaboration.
The ERA PerMed JTC2019 comprises three Research Areas:
Click to enlarge
ICT: Information and Communications Technology (or Technologies)
Each project proposal MUST address at least one module of Research Area 3 and at least one module of Research Area 1 or 2. The coherent integration and combination of the different Research Areas and Modules in the proposals is part of the evaluation process.
GENERAL (eligibility) CONDITIONS FOR APPLICATION
Applicants belonging to one of the following categories (A, B and/or C) may submit joint research proposals, if eligible according to relevant regional/national funding organisation regulations:
-
Academia (research teams working in universities, other higher education institutions) or research institutes;
-
Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses) in the research teams is encouraged;
-
(Industry) Private partners, e.g. SMEs[1] (small and medium-sized enterprises).
Please note
Although proposals will be submitted jointly by research groups from several regions/countries, research groups will be funded by the individual funding organisation of the respective region/country from which applicants have applied. Applications are therefore subject to eligibility criteria and regulations of individual funding organisations. In order to confirm their eligibility, applicants are strongly advised to contact their regional/national representatives of the participating relevant funding organisation prior to submission (see also “Contact details of participating members”).
|
Only transnational projects will be funded. Each consortium submitting a proposal must involve at least three partners eligible for funding coming from three different countries whose funding organisations participate to the call (see “Contact details of participating members”). All three legal entities must be independent of each other. The maximum number of partners per pre-proposal is six though no more than 2 partners from the same country participating in the call will be accepted in one project consortium (including those partners with own funding).
Research groups not eligible for funding (e.g. from non-funding countries or not fundable according to regional/national regulations of the participating funding organisation) may participate in transnational projects if they are able to secure their own funding. They are treated as full partners and must be included in the pre- and full-proposal templates as such. No more than one partner with its own funding is allowed in consortia with at least 3 partners that are eligible for funding. The coordinator must be eligible to be funded by the participating funding organisations to this call.
At the full-proposal stage, a consortium may be expanded to up to seven partners in total only by inclusion of a partner from an underrepresented country. A list of underrepresented countries will be provided to coordinators invited to submit full-proposals.
Click to enlarge
*minimum 3 partners eligible for funding from three different countries participating in the call
ICPerMed Partnering tool
If you are looking for potential partners, please have a look also at the ICPerMed Partnering Tool: https://partnering.pt-dlr.de/ICPerMed
Contact details of participating members
The further countries (22) are participating in the call: Austria, Belgium, Canada, Croatia, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Luxembourg, Norway, Poland, Romania, Spain, Sweden and Turkey.
The further regions (6) are participating in the call: Quebec (Canada), Saxon (Germany), Lombardy (Italy), Tuscany (Italy), Catalonia (Spain) and Navarre (Spain).
The contact list is provided below.
| Country |
Funding Organisation |
Contact point |
Email |
| AUSTRIA |
FWF |
Stephanie Resch
Iris Fortmann |
Stephanie.Resch@fwf.ac.at
Iris.Fortmann@fwf.ac.at |
| BELGIUM |
F.R.S.-FNRS |
Joël Groeneveld
Florence Quist |
joel.groeneveld@frs-fnrs.be
florence.quist@frs-fnrs.be |
| CANADA |
CIHR |
Ilana Gombos |
Ilana.Gombos@cihr-irsc.gc.ca |
| CANADA
(QUEBEC) |
FRQS |
Maxime Beaudoin |
Maxime.beaudoin@frq.gouv.qc.ca |
| CROATIA |
MSE |
Staša Skenžić |
Stasa.Skenzic@mzo.hr |
| DENMARK |
InnoFond |
Ejner Moltzen
Jens Peter Vittrup |
Ejner.moltzen@innofond.dk
Jens.peter.vittrup@innofond.dk |
| EGYPT |
ASRT |
Amr Radwan
Salma Essawi |
Radwan.Amro@gmail.com
Sme@sti.sci.eg,
innov@sti.sci.eg |
| FINLAND |
AKA |
Heikki Vilen |
heikki.vilen@aka.fi |
| FRANCE |
ANR |
Monika Frenzel |
ERAPerMed@agencerecherche.fr |
| GERMANY |
BMBF/DLR |
Dr. Katja Kuhlmann
Dr. Petra Lüers |
katja.kuhlmann@dlr.de Petra.Lueers@dlr.de |
| GERMANY |
BMG/VDI/VDE |
Dr. Anne Dwertmann
Dr. Andrea Repen |
Anne.Dwertmann@vdivde-it.de
Andrea.Repen@vdivde-it.de |
| GERMANY (SACHSEN) |
SMWK |
Eva Damm
Gabriele Süptitz |
permed@smwk.sachsen.de |
| GREECE |
GSRT |
Georgia Kostopoulou |
g.kostopoulou@gsrt.gr |
| HUNGARY |
NKFIH |
Dr. Klára Horváth |
klara.horvath@nkfih.gov.hu |
| IRELAND |
HRB |
Dr Caitriona Creely |
ccreely@hrb.ie |
| ISRAEL |
CSO-MOH |
Yahaloma Gat |
y.gat@moh.gov.il |
| ITALY |
IT-MoH |
Dr. Gaetano Guglielmi
Dr. Maria Josè Ruiz Alvarez |
g.guglielmi@sanita.it
mj.ruizalvarez-esterno@sanita.it |
| ITALY (LOMBARDY) |
FRRB |
Carmen De Francesco
Paola Larghi
Paola Bello |
carmen.defrancesco@frrb.it
paola.larghi@frrb.it
paola.bello@frrb.it |
| ITALY (TUSCANY) |
TUSCREG |
Donatella Tanini
Teresa Vieri |
erapermed@regione.toscana.it |
| LATVIA |
VIAA |
Maija Bundule
Uldis Berkis |
Maija.Bundule@viaa.gov.lv
Uldis.Berkis@viaa.gov.lv |
| LUXEMBOURG |
FNR |
Marie-Claude Marx |
marie-claude.marx@fnr.lu |
| NORWAY |
RCN |
Karianne Solaas |
kso@rcn.no |
| POLAND |
NCBR |
Marcin Chmielewski |
marcin.chmielewski@ncbr.gov.pl |
| ROMANIA |
UEFISCDI |
Cristina Laura COTET |
cristina.cotet@uefiscdi.ro |
| SPAIN |
ISCIII |
Mauricio García-Franco
Eduard Güell |
mauriciog@isciii.es
eranetpm@isciii.es |
| SPAIN |
CDTI |
Sara Alfonso |
sara.alfonso@cdti.es |
| SPAIN |
AECC-FC |
Marta Puyol |
marta.puyol@aecc.es |
| SPAIN (CATALONIA) |
DS-CAT |
Montserrat Llavayol |
peris@gencat.cat |
| SPAIN (NAVARRE) |
GN |
Sara Torres |
storresl@navarra.es |
| SWEDEN |
SRC |
Malin Eklund |
Malin.Eklund@vr.se |
| TURKEY |
TUBITAK |
Banu Gökcay |
banu.buruk@tubitak.gov.tr |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en
